BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32238406)

  • 1. Prediagnostic 25-Hydroxyvitamin D Concentrations in Relation to Tumor Molecular Alterations and Risk of Breast Cancer Recurrence.
    Peng C; Heng YJ; Lu D; DuPre NC; Kensler KH; Glass K; Zeleznik OA; Kraft P; Feldman D; Hankinson SE; Rexrode K; Eliassen AH; Tamimi RM
    Cancer Epidemiol Biomarkers Prev; 2020 Jun; 29(6):1253-1263. PubMed ID: 32238406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma 25-Hydroxyvitamin D and Risk of Breast Cancer in Women Followed over 20 Years.
    Eliassen AH; Warner ET; Rosner B; Collins LC; Beck AH; Quintana LM; Tamimi RM; Hankinson SE
    Cancer Res; 2016 Sep; 76(18):5423-30. PubMed ID: 27530324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: The Melbourne Collaborative Cohort Study.
    Heath AK; Hodge AM; Ebeling PR; Eyles DW; Kvaskoff D; Buchanan DD; Giles GG; Williamson EJ; English DR
    Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):900-908. PubMed ID: 30842127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D Receptor in Breast Cancer Tissues and Its Relation to Estrogen Receptor Alpha (ER-α) Gene Expression and Serum 25-hydroxyvitamin D Levels in Egyptian Breast Cancer Patients: A Case-control Study.
    Hemida MA; AbdElmoneim NA; Hewala TI; Rashad MM; Abdaallah S
    Clin Breast Cancer; 2019 Jun; 19(3):e407-e414. PubMed ID: 30833174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.
    McDonnell SL; Baggerly CA; French CB; Baggerly LL; Garland CF; Gorham ED; Hollis BW; Trump DL; Lappe JM
    PLoS One; 2018; 13(6):e0199265. PubMed ID: 29906273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study.
    Yao S; Sucheston LE; Millen AE; Johnson CS; Trump DL; Nesline MK; Davis W; Hong CC; McCann SE; Hwang H; Kulkarni S; Edge SB; O'Connor TL; Ambrosone CB
    PLoS One; 2011 Feb; 6(2):e17251. PubMed ID: 21386992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating 25-hydroxyvitamin D and postmenopausal breast cancer survival: Influence of tumor characteristics and lifestyle factors?
    Vrieling A; Seibold P; Johnson TS; Heinz J; Obi N; Kaaks R; Flesch-Janys D; Chang-Claude J
    Int J Cancer; 2014 Jun; 134(12):2972-83. PubMed ID: 24272459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D and breast cancer recurrence in the Women's Healthy Eating and Living (WHEL) Study.
    Jacobs ET; Thomson CA; Flatt SW; Al-Delaimy WK; Hibler EA; Jones LA; Leroy EC; Newman VA; Parker BA; Rock CL; Pierce JP
    Am J Clin Nutr; 2011 Jan; 93(1):108-17. PubMed ID: 20980485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies.
    Bauer SR; Hankinson SE; Bertone-Johnson ER; Ding EL
    Medicine (Baltimore); 2013 May; 92(3):123-131. PubMed ID: 23625163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of early menarche with breast tumor molecular features and recurrence.
    Harris AR; Wang T; Heng YJ; Baker GM; Le PA; Wang J; Ambrosone C; Brufsky A; Couch FJ; Modugno F; Scott CG; Vachon CM; Hankinson SE; Rosner BA; Tamimi RM; Peng C; Eliassen AH
    Breast Cancer Res; 2024 Jun; 26(1):102. PubMed ID: 38886818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: a nested case-control study.
    Kühn T; Kaaks R; Becker S; Eomois PP; Clavel-Chapelon F; Kvaskoff M; Dossus L; Tjønneland A; Olsen A; Overvad K; Chang-Claude J; Lukanova A; Buijsse B; Boeing H; Trichopoulou A; Lagiou P; Bamia C; Masala G; Krogh V; Sacerdote C; Tumino R; Mattiello A; Buckland G; Sánchez MJ; Menéndez V; Chirlaque MD; Barricarte A; Bueno-de-Mesquita HB; van Duijnhoven FJ; van Gils CH; Bakker MF; Weiderpass E; Skeie G; Brustad M; Andersson A; Sund M; Wareham N; Khaw KT; Travis RC; Schmidt JA; Rinaldi S; Romieu I; Gallo V; Murphy N; Riboli E; Linseisen J
    Int J Cancer; 2013 Oct; 133(7):1689-700. PubMed ID: 23526380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer.
    Li H; Stampfer MJ; Hollis JB; Mucci LA; Gaziano JM; Hunter D; Giovannucci EL; Ma J
    PLoS Med; 2007 Mar; 4(3):e103. PubMed ID: 17388667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels.
    Peppone LJ; Rickles AS; Janelsins MC; Insalaco MR; Skinner KA
    Ann Surg Oncol; 2012 Aug; 19(8):2590-9. PubMed ID: 22446898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Nucleotide Polymorphisms in Vitamin D-Related Genes May Modify Vitamin D-Breast Cancer Associations.
    O'Brien KM; Sandler DP; Kinyamu HK; Taylor JA; Weinberg CR
    Cancer Epidemiol Biomarkers Prev; 2017 Dec; 26(12):1761-1771. PubMed ID: 28830874
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II.
    Eliassen AH; Spiegelman D; Hollis BW; Horst RL; Willett WC; Hankinson SE
    Breast Cancer Res; 2011 May; 13(3):R50. PubMed ID: 21569367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative Impact of 25-hydroxyvitamin D Deficiency on Breast Cancer Survival.
    Thanasitthichai S; Prasitthipayong A; Boonmark K; Purisa W; Guayraksa K
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):3101-3106. PubMed ID: 31653160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Premenopausal plasma 25-hydroxyvitamin D, mammographic density, and risk of breast cancer.
    Bertrand KA; Rosner B; Eliassen AH; Hankinson SE; Rexrode KM; Willett W; Tamimi RM
    Breast Cancer Res Treat; 2015 Jan; 149(2):479-87. PubMed ID: 25543181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival.
    Yuan C; Qian ZR; Babic A; Morales-Oyarvide V; Rubinson DA; Kraft P; Ng K; Bao Y; Giovannucci EL; Ogino S; Stampfer MJ; Gaziano JM; Sesso HD; Buring JE; Cochrane BB; Chlebowski RT; Snetselaar LG; Manson JE; Fuchs CS; Wolpin BM
    J Clin Oncol; 2016 Aug; 34(24):2899-905. PubMed ID: 27325858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women.
    de Sousa Almeida-Filho B; De Luca Vespoli H; Pessoa EC; Machado M; Nahas-Neto J; Nahas EAP
    J Steroid Biochem Mol Biol; 2017 Nov; 174():284-289. PubMed ID: 29031688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D-related gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk.
    Reimers LL; Crew KD; Bradshaw PT; Santella RM; Steck SE; Sirosh I; Terry MB; Hershman DL; Shane E; Cremers S; Dworakowski E; Teitelbaum SL; Neugut AI; Gammon MD
    Cancer Causes Control; 2015 Feb; 26(2):187-203. PubMed ID: 25421379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.